Cardioprotective effect of intravenous nicorandil in patients with successful reperfusion for acute myocardial infarction.
This study was designed to assess the cardioprotective effect of intravenous nicorandil, a potassium channel opener, in preventing reperfusion injury in acute myocardial infarction. Seventy patients were treated with placebo or nicorandil concomitant with reperfusion therapy in a prospective, randomized, double-blind fashion within 6 h after the onset of acute myocardial infarction. Nicorandil was administered before reperfusion as a 2-mg bolus iv injection followed by continuous infusion of 2-6 mg/h for the next 3 h. Thirty-six patients (17 in the placebo group, 19 in the nicorandil group) who demonstrated both complete occlusion of an infarct-related vessel before treatment and successful reperfusion were included in the final analysis. No significant changes in left ventricular ejection fraction were observed between the immediate and chronic phases in each group. In the analysis of regional ventricular function, the placebo group did not show any significant change in regional chord shortening (26.8+/-8.2 vs 24.3+/-7.3%, NS) or hypocontractile perimeter (36.4+/-28.2% vs 28.3+/-24.8%, NS) between immediate and chronic phase left ventriculograms. In contrast, in the nicorandil group, a significant increase in regional chord shortening (21.5+/-11.0% vs 25.8+/-11.3%, p<0.05) and a significant decrease in hypocontractile perimeter (33.3+/-19.6% vs 25.6+/-24.3%, p<0.05) were observed in the chronic phase left ventriculogram. Thus, nicorandil may be a useful adjunctive therapy for preserving myocardial contractile function in patients with acute myocardial infarction undergoing reperfusion therapy.
Kobayashi
Y
Y
Department of Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Goto
Y
Y
Daikoku
S
S
Itoh
A
A
Miyazaki
S
S
Ohshima
S
S
Nonogi
H
H
Haze
K
K
D000208:Acute Disease; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000503:physiopathology*; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D020108:Nicorandil; D015221:Potassium Channels / Q000819:agonists
D000889:Anti-Arrhythmia Agents; D015221:Potassium Channels; D009536:Niacinamide; D020108:Nicorandil